Aisling Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Aisling Capital Management's GLUE Position: Q3 2026 in Review
Aisling Capital Management held its Monte Rosa Therapeutics (GLUE) position steady in Q3 2026 at 1,555,664 shares worth $18.6M. The position accounts for 6.2% of the portfolio, ranked #4.
Aisling Capital Management first reported a position in GLUE in Q2 2021 and has held it in 22 quarters since. The position peaked at $37.6M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Aisling Capital Management held 1,555,664 shares of Monte Rosa Therapeutics worth $18.6M as of Q3 2026.
- Aisling Capital Management left its Monte Rosa Therapeutics share count unchanged in Q3 2026.
- Monte Rosa Therapeutics made up 6.2% of Aisling Capital Management's portfolio in Q3 2026, its #4 holding.
- Aisling Capital Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 22 quarters since.
- Aisling Capital Management's Monte Rosa Therapeutics position peaked at $37.6M in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Aisling Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.